Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual MeetingBusiness Wire • 12/01/25
Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer's Disease in JapanGlobeNewsWire • 11/28/25
Biogen Inks Research Deal With Dayra to Boost Immunology PipelineZacks Investment Research • 11/25/25
Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track StatusGlobeNewsWire • 11/25/25
Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological ConditionsGlobeNewsWire • 11/24/25
Versant Ventures Announces Launch of Dayra Therapeutics With Foundational Biogen PartnershipBusiness Wire • 11/24/25
Novo Nordisk Stock Falls After Ozempic Fails to Slow Alzheimer's in Trials. Biogen Jumps.Barrons • 11/24/25
Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer's Disease ConferenceGlobeNewsWire • 11/20/25
Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral ImpairmentsGlobeNewsWire • 11/17/25
Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral ImpairmentsBusiness Wire • 11/17/25
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular AtrophyGlobeNewsWire • 11/17/25
Biogen Inc. (BIIB) Presents at TD Cowen Immunology and Inflammation Summit TranscriptSeeking Alpha • 11/13/25
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United KingdomGlobeNewsWire • 11/13/25
Biogen Inc. (BIIB) Presents at Wedbush Rewind ASN 2025 Conference Prepared Remarks TranscriptSeeking Alpha • 11/10/25
Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025GlobeNewsWire • 11/03/25
BIIB Beats on Q3 Earnings & Sales, Stock Down on Lowered '25 EPS ViewZacks Investment Research • 10/30/25
Biogen (BIIB) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 10/30/25